Cargando…

HSP90 as an emerging barrier to immune checkpoint blockade therapy

Immunotherapy, especially the use of immune checkpoint inhibitors, has improved overall survival in cancer patients. However, a large proportion of patients initially do not respond to treatment or relapse after a period of response. Heat shock protein 90 (HSP90) is a conserved molecular chaperone t...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Daolin, Kang, Rui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033023/
https://www.ncbi.nlm.nih.gov/pubmed/35479647
http://dx.doi.org/10.18632/oncoscience.554